Floatz logo

Afa-281

Lumbosacral Radiculopathy

Afasci IncPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

18 Active assets in the Lumbosacral Radiculopathy cohort.

Asset / SponsorPhaseRating
LIDOCAINE
C.L.A.Vleggeert-Lankamp
Phase 4BBB
DEXAMETHASONE
University of Miami
Phase 4BBB
NEPENTHE
Akdeniz University
Phase 4BB
Naproxen
Ostfold Hospital Trust
Phase 4BB
(RS)-KETOPROFEN
University Hospital, Grenoble
Phase 4BB

View all 45 →

Same molecule, other indications

Afa-281 is also rated in:

neuralgiaDormant
CC
Indicative ·
47 / 100
View asset →
inflammatory diseaseDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →